There are currently 122 clinical trials in Pasadena, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Keck Medical Center of USC Pasadena, Huntington Memorial Hospital, California Liver Research Institute and Lotus Clinical Research, LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
NCT05869669
Recruiting
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.
Gender:
All
Ages:
55 years and above
Trial Updated:
03/25/2024
Locations: SC3 Research Group, Pasadena, California
Conditions: Dementia With Lewy Bodies
Register for Updates
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222
Recruiting
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: California Liver Research Institute, Pasadena, California
Conditions: NASH, Cirrhosis, Liver
Register for Updates
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526
Recruiting
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
03/20/2024
Locations: Havana Research Institute, Pasadena, California
Conditions: Alzheimer Disease
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Huntington Memorial Hospital, Pasadena, California
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Kaiser Permanente Evaluating Nutritional Interventions in Food-Insecure High-Risk Adults Study
NCT06061861
Recruiting
The goal of this randomized controlled trial is to compare the effect of receiving 6 months of monetary support for healthy food through a food delivery platform on change in glycosylated hemoglobin (HbA1c) levels among adults with type 2 diabetes mellitus with glycemic control that is above target level. The main study aims are to: To evaluate whether providing monthly financial support for home-delivered healthy food vs. only free food delivery through the Instacart platform reduces glycosyl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids
NCT05143697
Recruiting
Primary care settings lack interventions to address the childhood obesity epidemic that are feasible and sustainable without requiring significant resources. The investigators propose to modify and test an intervention shown to lower children's body mass index(BMI) so that it is feasible, sustainable, and easily disseminated in a real-world clinical setting. If successful, the investigators will be able to provide recommendations to providers and health care systems that help prioritize future i... Read More
Gender:
All
Ages:
Between 2 years and 8 years
Trial Updated:
03/14/2024
Locations: Kaiser Permanente Pasadena, Pasadena, California
Conditions: Obesity
Register for Updates
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Pasadena Clinical Research, Pasadena, California
Conditions: Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
Register for Updates
Implementation of Evidence-Based Practice for Dizziness
NCT05634902
Recruiting
The study evaluates the implementation of evidence-based practice for the management of patients with dizziness in the emergency department (ED) within a large integrated health care system. The clinical focus is on benign paroxysmal positional vertigo (BPPV), unilateral vestibulopathy (e.g., vestibular neuritis), and stroke - which are disorders with established evidence-base practices for evaluation and management. Evidence-based practices for these clinical topics have not properly disseminat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/04/2024
Locations: Kaiser Permanente Southern California, Pasadena, California
Conditions: BPPV, Vestibular Diseases, Vertigo, Dizziness
Register for Updates
Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis
NCT05384249
Recruiting
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin-17A, to which it binds with high affinity. This study investigates izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/29/2024
Locations: Clinical Research Site, Pasadena, California
Conditions: Uveitis
Register for Updates
Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
NCT03041688
Recruiting
This phase Ib trial studies the side effects and best dose of navtemadlin when given together with decitabine and venetoclax in treating patients with acute myeloid leukemia that has come back after a period of improvement (recurrent), does not respond to treatment (refractory), or is newly diagnosed. Navtemadlin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as decitabine, work in different ways to stop the growth of cancer c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: Keck Medical Center of USC Pasadena, Pasadena, California
Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Register for Updates
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
NCT04909450
Recruiting
This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm. All subjects will dose with the randomized treatment four times daily for 8 weeks (controlled treatment phase). During the controlled treatment phase, subjects will return to the clinic weekly from Day 0 to Week 8, and again at Week 10. Subjects randomized to the vehicle arm who are not healed will have the oppor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: California Eye Specialists Medical Group Inc., Pasadena, California
Conditions: Neurotrophic Keratitis
Register for Updates
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT04630808
Recruiting
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
Gender:
All
Ages:
Between 18 years and 84 years
Trial Updated:
02/23/2024
Locations: Nicox Clinical Site, Pasadena, California
Conditions: Open Angle Glaucoma, Ocular Hypertension
Register for Updates